Key Points
- China’s NHSA and NHC have launched “Several Measures to Support the High-Quality Development of Innovative Drugs,” a comprehensive framework providing 16 “systemic dividends” across the drug lifecycle, from R&D to market payment.
- A major innovation is the establishment of a “commercial health insurance innovative drug catalog,” marking the first time commercial health insurance is systematically integrated into China’s healthcare strategy.
- The new policy aims to create synergy between basic and commercial medical insurance through coverage, data, settlement, and supervision collaboration, as highlighted by Huang Xinyu (黄心宇).
- Market reaction was positive, with the Hang Seng Biotech ETF (159615.SZ) and Innovative Drug ETF (159622.SZ) surging, and innovative drug stocks like Shatshn (舒泰神) seeing gains on announcement day.
- Experts see the Measures providing long-term structural benefits, including data-powered R&D, “point-to-point” guidance for market access, formal inclusion of Real-World Studies (RWS) in drug evaluation, and reduced hospital entry barriers for new drugs.
The landscape for China’s innovative drugs is on the cusp of a seismic shift.
In a major move signaling top-level support for the biotech and pharma industries, China’s National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) have jointly rolled out a new policy framework.
This isn’t just another incremental update.
Published today, the “Several Measures to Support the High-Quality Development of Innovative Drugs” (let’s call it “the Measures”) offers a comprehensive, top-down design for the entire lifecycle of an innovative drug—from R&D to market payment.
This is the medical insurance system actively ‘shaking hands’ with the innovative drug industry, and it’s a huge deal.
Let’s break down what’s inside.
The 16 “Systemic Dividends”: A New Framework for Pharma Innovation
The new Measures are built around five key pillars and sixteen specific provisions, creating a robust support system for drug development.
It’s a complete overhaul aimed at driving high-quality development, and it’s being powered by both basic medical insurance and a new multi-tiered payment system.
The core focus areas include:
- Research & Development (R&D): Fostering a new R&D paradigm guided by real clinical value. This includes providing medical insurance data support and encouraging more significant investment from companies.
- Market Access & Payment: The big one. The policy aims to build a diversified payment system, broadening the channels for how innovative drugs get paid for.
- Clinical Use: Improving the accessibility and real-world use of new drugs by tackling bottlenecks in hospital admission, payment, and allocation.
- Internationalization: Actively encouraging and helping Chinese innovative drugs to “go global” and tap into international markets.
But the most groundbreaking piece of this entire framework is the formal introduction of a commercial insurance program.
Resume Captain
Your AI Career Toolkit:
- AI Resume Optimization
- Custom Cover Letters
- LinkedIn Profile Boost
- Interview Question Prep
- Salary Negotiation Agent
The Game-Changer: A Commercial Health Insurance Innovative Drug Catalog
For the first time, commercial health insurance is being systematically woven into China’s national healthcare strategy.
The government is officially establishing a “commercial health insurance innovative drug catalog.”
This is a massive development.
During a press conference, Huang Xinyu (Huang Xinyu 黄心宇), Director of the Medical Service Management Department at the NHSA, explained the move.
“We will ensure the 衔接 (xiánjiē, connection) between the medical insurance drug catalog and the commercial insurance innovative drug catalog,” he stated. “This will provide a stable outlet for drugs… better stabilize corporate expectations, and further improve drug accessibility.”
Here’s the key takeaway:
The NHSA will handle the compilation of this new commercial catalog, leveraging its existing expertise to streamline the process for drug companies. No more multiple, burdensome submissions.
The government is billing this as “the first step towards meeting the diverse medication needs of the public.” It clearly defines the limits of basic medical insurance and carves out a massive space for commercial insurers to grow.
How Public and Commercial Insurance Will Collaborate
Huang Xinyu outlined four key areas of synergy between basic medical insurance and the new commercial system:
- Coverage Synergy: The commercial catalog will complement the basic one, leaving “ample room for the development of commercial health insurance.”
- Data Synergy: The NHSA will explore empowering commercial insurance with its massive trove of medical data to support faster underwriting, claims processing, and the development of new insurance products. The goal is to shift from insuring healthy people to ensuring the health of people.
- Settlement Synergy: Patients with commercial insurance could see synchronized, one-stop settlements at medical institutions.
- Supervision Synergy: The NHSA will share its intelligent supervision platform to create coordinated oversight between the two systems.
Important note: Inclusion in the commercial catalog is recommended, not mandatory for insurance companies. An official stated, “This is a market behavior… the prices should also be negotiated.”
- Coverage Synergy: Commercial catalog complements basic, creating room for commercial health insurance growth.
- Data Synergy: NHSA data to empower commercial insurance for better underwriting, claims, and new products; shifting focus to “ensuring the health of people.”
- Settlement Synergy: One-stop, synchronized settlements for commercially insured patients at medical institutions.
- Supervision Synergy: NHSA’s intelligent supervision platform to coordinate oversight across both systems.
Find Top Talent on China's Leading Networks
- Post Across China's Job Sites from $299 / role, or
- Hire Our Recruiting Pros from $799 / role
- Qualified Candidate Bundles
- Lower Hiring Costs by 80%+
- Expert Team Since 2014
Your First Job Post
Market & Company Reactions: A Jolt of Confidence
The capital markets responded immediately.
On the day of the announcement, the Hang Seng Biotech ETF (159615.SZ) and the Innovative Drug ETF (159622.SZ) both surged.
Innovative drug stocks like Shatshn (Shutaishn 舒泰神), RemeGen (Rongchang Xiyao 荣昌生物), and Hotgen Biotech (ReiJing Shengwu 热景生物) all saw gains.
A representative from Sino Biopharmaceutical (Zhongguo Shengwu Zhiyao 中国生物制药) praised the move, noting that it addresses several key pain points for the industry.
“These measures are expected to break the long-standing challenges of low pricing for 国产 (guóchǎn, domestically produced) innovative drugs and insufficient returns on R&D,” the representative said. “Sino Biopharmaceutical will… continue to spare no effort in increasing investment in innovative drug R&D.”
They also highlighted plans to help other companies in the chain explore markets along the “Belt and Road” (Yidai Yilu 一带一路) initiative.
Similarly, a rep from Efun Pharmaceutical (Yifan Yi Yao 亿帆医药) stated the Measures will be crucial for the industry’s high-quality development, helping to “stimulate R&D vitality” and benefit innovative companies in the long run.
ExpatInvest China
Grow Your RMB in China:
- Invest Your RMB Locally
- Buy & Sell Online in CN¥
- No Lock-In Periods
- English Service & Data
- Start with Only ¥1,000
The Expert Take: Restructuring and Unleashing Growth Potential
Industry insiders see the Measures as providing long-term structural benefits rather than just short-term subsidies.
Jin Chunlin (Jin Chunlin 金春林), Director of the Shanghai Health and Health Development Research Center, called the policy “systematic and tightly structured,” with a logic that is “very clear from beginning to end.”
He highlighted several game-changing elements:
- Data-Powered R&D: Using medical insurance data to guide company pipeline layouts is a major breakthrough.
- “Point-to-Point” Guidance: Allowing companies to start communicating with the medical insurance agency from the moment of regulatory acceptance will dramatically improve the success rate of market access.
- Real-World Studies (RWS) Matter: For the first time, RWS are formally part of the renewal and payment adjustment process. A drug’s performance in the real world—not just in clinical trials—will determine its future.
- Breaking Down Hospital Barriers: Policies to relax the “one product, two specifications” rule and limit review times are expected to provide “structural relief” for new drugs trying to get into hospitals.
Zhao Heng (Zhao Heng 赵衡), founder of consulting firm LatitudeHealth, added that the new rules bring practical benefits that stabilize long-term expectations for companies.
“The renewal mechanism explicitly states that if drug sales exceed expectations… the price reduction amount cannot exceed that allowed for simplified renewal,” Zhao explained. “This stabilizes companies’ long-term pricing expectations.”
He also pointed out a key detail: drugs in the commercial catalog won’t be included in out-of-pocket medical insurance ratio calculations or monitored as part of centralized procurement. This gives pharma companies a new, compliant sales channel characterized by “low volume and no monitoring.”
While Zhao praised the overall direction, he offered a dose of realism, cautioning that “structural barriers still exist in hospital performance evaluations, requiring further detailed implementation.”
The Bottom Line
This policy overhaul is a clear signal from Beijing. The government is moving away from direct subsidies and instead focusing on structural deregulation to create a healthier, more sustainable ecosystem for pharma innovation.
By creating new payment channels, leveraging data, and rewarding true clinical value, this package of “systemic dividends” is designed to unleash the long-term growth potential of China’s innovative drugs sector.
![Magnetic Levitation Compressors: Skyrocketing Demand & Hot Stocks in the AI Era [FreshFromChina]](https://freshfromchina.com/wp-content/uploads/2025/05/magnetic_levitation_compressors_skyrocketing_demand_hot_stocks_ai_era.png____FreshFromChina-150x150.png)
